A monthly injection could help people with severe asthma come off daily steroid tablets entirely without any impact on symptoms, a trial has found. Tezepelumab – also known as Tezspire and made by ...

Facing increased competition in the weight loss market and intense pressure from President Donald Trump, Novo Nordisk announced Monday that it is lowering prices for its blockbuster obesity and ...

Adocia has announced the filing of a patent for its new long-acting peptide platform, AdoXLong, aimed at improving treatment options for diabetes and obesity. The French biopharmaceutical company said ...

ADVANCING MOST-FAVORED-NATION (MFN) PRICING: Today, President Donald J. Trump announced the latest in a series of the most significant actions ever taken by our Federal government to lower ...

Diabetes is one of the most prevalent health challenges in the United States, affecting millions of Americans every day. According to the American Diabetes Association, more than 38 million people ...

Make your budget work for your real lifestyle—not the one on spreadsheets Vikki Velasquez is a researcher and writer who has managed, coordinated, and directed various community and nonprofit ...

Novo Nordisk said on Monday it is offering its diabetes drug Ozempic for $499 per month to eligible cash-paying type 2 diabetes patients in the U.S. The company said in March that it was cutting the ...

MAKING AMERICA THE LEADER IN DIGITAL ASSETS: Today, President Donald J. Trump signed the GENIUS Act into law, a historic piece of legislation that will pave the way for the United States to lead the ...

The MarketWatch News Department was not involved in the creation of this content. MariTide, the First Monthly or Less Frequently Dosed Obesity Treatment, Demonstrated Up to 20% Average Weight Loss ...

MariTide, the First Monthly or Less Frequently Dosed Obesity Treatment, Demonstrated Up to ~20% Average Weight Loss Without a Weight Loss Plateau, and Delivered Significant Cardiometabolic ...

The MARITIME Phase 3 Chronic Weight Management Studies are Actively Enrolling, and Phase 3 Studies in People Living With Atherosclerotic Cardiovascular Disease, Heart Failure and Obstructive Sleep ...

End points were measured from baseline to week 52. Values are derived from an analysis of variance for the treatment policy estimand (top part of table) and a mixed-model-for-repeated-measures ...